Keytruda
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid cancers.
Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
Prelude Therapeutics to Study PRT3789, Keytruda in SMARCA4-Mutant Cancers
Prelude is currently evaluating PRT3789 as a monotherapy and in combination with docetaxel in a Phase I study with SMARCA4-mutated tumors.
Merck, Moderna Personalized Neoantigen Vaccine, Keytruda Combo Still Benefiting Melanoma Patients
Premium
After three years of follow-up, mRNA-4157 plus Keytruda led to a 49 percent reduction in the risk of disease recurrence or death versus Keytruda alone.
Apr 25, 2024
Merck's Keytruda Sales Increase 20 Percent in Q1
Nov 14, 2023